Botulinum toxin treatment of the buccinator muscle facial synkinesis: A systematic review.

J Plast Reconstr Aesthet Surg

Department of General, Abdominal Surgery and Coloproctology, Helios St. Elisabeth Klinik, Oberhausen, NRW, Germany; Department of Intensive Care Medicine, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands; Faculty of Health, Witten/Herdecke University, Witten, Germany. Electronic address:

Published: November 2023

Background: The purpose of this review is to provide an overview of the available literature assessing the treatment of botulinum toxin injections for the treatment of synkinesis of the buccinator muscle in patients with peripheral facial palsy (PFP).

Materials And Methods: A multi database search was performed, including the following databases: Pubmed, Medline, Embase, and the Cochrane Library. Each database was searched from its earliest date until 8 June 2023. The following outcome measures were extracted from the articles when available: subjective, somatic, and psychological effects on the patients and objective outcomes such as the House-Brackmann, Sunnybrook and Sydney scores. The methodological quality of the included studies was rated using the Newcastle-Ottawa scale for nonrandomised trials.

Results: The primary literature search generated 37 articles. After removing duplicates, 25 articles remained for abstract appraisal, of which 20 underwent full-text appraisal, resulting in 3 studies for analysis. All of these studies showed (significant) improvement in synkinesis either measured using the Synkinesis Assessment Questionnaire or subjectively measured by asking treated patients.

Conclusion: The available literature supports the finding that botulinum toxin treatment of the buccinator muscle could be a welcome addition to facial synkinesis treatment and could significantly improve patient outcomes. In future studies, the efficacy of EMG-guided buccinator injections, optimal dose, and a validated measuring method could be beneficial in optimising treatment for patients with a PFP and synkinesis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjps.2023.08.006DOI Listing

Publication Analysis

Top Keywords

botulinum toxin
12
buccinator muscle
12
toxin treatment
8
treatment buccinator
8
facial synkinesis
8
treatment
6
synkinesis
6
buccinator
4
muscle facial
4
synkinesis systematic
4

Similar Publications

Objective: Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI).

Material And Methods: A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18-75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups.

View Article and Find Full Text PDF

[Investigation of general toxic effects of Relatox in comparison with Dysport].

Zh Nevrol Psikhiatr Im S S Korsakova

December 2024

OOO NBC «Pharmbiomed», Moscow, Russia.

Objective: To evaluate the toxic effects of the agent Relatox on mature outbred rats and mice in an acute experiment in comparison with the registered analogue Dysport.

Material And Methods: Based on the aim of experiment, the acute toxic effects of Relatox and Dysport were assessed on two animal species: rats and mice at intraperitoneal and intramuscular administration at dose levels that made it possible to calculate the toxicological parameter values (initially 10-150 U/kg with subsequent usage of additional doses 20 U/kg to 300 U/kg depending on the agent and route of administration). The LD values and other acute toxic parameters were calculated using probit analysis.

View Article and Find Full Text PDF

Oromandibular dystonia (OMD) is a focal dystonia characterized by contractions of the masticatory, lingual, and other muscles of the stomatognathic system. We conducted a systematic review and meta-analysis to elucidate the impact and safety of botulinum toxin in OMD. The eligibility criteria were full-length original articles that provided data evaluating the efficacy and adverse effects of onabotulinumtoxinA injections in patients with OMD.

View Article and Find Full Text PDF

Botulinum Toxin and Migraine: Goals and Perspectives.

Toxins (Basel)

December 2024

Headache Center, Neurological Clinic, "L. Amaducci", AOUC Policlinico, Piazza G. Cesare, 11, 70124 Bari, Italy.

This Special Issue aims to provide an updated overview of the current state and future perspectives of botulinum toxin treatment for migraine [...

View Article and Find Full Text PDF

Integrating Telemedicine in Botulinum Toxin Type-A Treatment for Spasticity Management: Perspectives and Challenges from Italian Healthcare Professionals.

Toxins (Basel)

December 2024

Spasticity and Movement Disorders "ReSTaRt", Physical Medicine and Rehabilitation Section, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.

(1) Background: Telemedicine is a vital tool for enhancing healthcare accessibility and outcomes at reduced costs. This study aimed to assess the usability of the Maia Connected Care telemedicine platform for managing spasticity in patients receiving botulinum toxin type-A, focusing on the perspectives of Italian physiatrists with expertise in this treatment. (2) Methods: Conducted from March 2023 to June 2023, this multicenter survey involved 15 Italian physicians who used the platform for teleconsultations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!